Oslo, Norway, 30 September 2016 - Serodus ASA (OSE: SER): Reference is made to the 2. Quarterly report 2016 where Serodus stated that an evaluation of the financing model including the listing at Oslo Axess will be made.

Serodus has, as part of the financing strategy presented the portfolio to international pharmaceutical companies as well as to professional life science funds. The feedback on the pipeline and scientific rationale behind the individual projects has been very positive with a willingness to further dialogue when data are available. However, international life science investors have expressed a general and significant reluctance to invest in a public company in what is described as a limited biotech market. It is therefore prudent to consider alternative routes for future long-term financing in line with the anticipated needs of the company.

Based on the arguments above Serodus has together with the largest shareholder of the company decided to evaluate the possibilities for a de-listing from Oslo Axess, by approaching shareholders of the company in order get their acceptance for this strategy. Provided that that the sufficient support accomplished during these discussions, it is expected that the largest shareholder will give a voluntary offer for the company with an objective to delist from Oslo Axess.

For more information please consult www.serodus.com or contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of diabetes and diabetic comorbidities with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see www.serodus.com.

Serodus ASA published this content on 30 September 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 October 2016 11:18:03 UTC.

Original documenthttp://www.serodus.com/News/2016/Evaluating-financing-model

Public permalinkhttp://www.publicnow.com/view/73844C48EDEC08177E527E799051310D8E314AA2